Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
What is the purpose of this trial?
The purpose of this study is to determine if an investigational treatment (Maribavir) is safe and effective in treating transplant recipient patients with cytomegalovirus (CMV) infections that are refractory or resistant to treatment.
- Ages12 - 80 years
- Trial withShire ViroPharma, Inc.
- Start Date01/23/2018
- End Date05/30/2019
- Last Updated04/09/2018
- Study HIC#2000020766